Medine.co.uk

Cobactan Mc Intramammary Suspension 75 Mg Milking Cow

Revised: June 2014

AN: 00287/2014


Summary of product characteristics


NAME OF the VETERINARY MEDICINAL PRODUCT


Cobactan MC Intramammary Suspension 75 mg Milking Cow


QUALITATIVE AND QUANTITATIVE COMPOSITION


Per 8g syringe:


Active substance:

Cefquinome 75.0mg

(as cefquinome sulphate)


For full list of excipients, see section 6.1


PHARMACEUTICAL FORM


Intramammary Suspension

White to slightly yellow, oily viscous homogeneous intramammarysuspension


CLINICAL PARTICULARS


Target species


Lactating cows


Indications for use, specifying the target species


For the treatment of clinical mastitis in the lactating dairy cow caused by bacteria susceptible to cefquinome.


Contra-indications


Not to be administered to animals which are known to be hypersensitive to cephalosporin antibiotics.

There may be cross sensitivity to penicillins.


Special warning for each target species


None

Special precautions for use


Special precautions for use in animals


None


Special precautions to be taken by the person administering the medicinal product to the animals


When infusing heifers protective gloves should always be worn in order to avoid skin contact.


Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross sensitivity to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious.


Do not handle this product if you know you are sensitised, or if you have been advised not to work which such preparations.


Handle this product with great care to avoid exposure, taking all recommended precautions.


If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the Doctor this warning. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.


Wash hands after use.


Adverse reactions (frequency and seriousness)


None known


Use during pregnancy or lactation


The product is intended for use during lactation. No restrictions apply for use during pregnancy.


Interaction with other medicinal products and other forms of interaction


There is a cross sensitivity between the various cephalosporins.

Amounts to be administered and administration route


The contents of one syringe should be infused gently into the teat of the infected quarter every 12 hours after each of three successive milkings.

Milk out the affected quarter(s). After thoroughly cleaning and disinfecting the teat and teat orifice, gently infuse the contents of one syringe into each affected quarter. Disperse the product by gentle massage of the teat and udder of the affected animal.


Further Information:

Combined Therapy

For the treatment of E.colimastitis, experimental challenge studies have shown that the use of this product in combination with Cobactan 25 mg/ml suspension for injection leads to an improvement in efficacy, particularly in terms of bacterial cure rate.

For combined therapy the following treatment regime should be followed:


Cobactan 25 mg/ml

Cobactan MC


1mg cefquinome/kg bw

(2ml/50 kg bw)



24 hours



1mg cefquinome/kg bw

(2ml/50 kg bw)



One syringe gently infused into the teat of the infected quarter


12 hours


One syringe gently infused into the teat of the infected quarter


12 hours


One syringe gently infused into the teat of the infected quarter



Overdose (symptoms, emergency procedures, antidotes), if necessary


No symptoms expected or emergency procedures required.


Withdrawal periods


Meat and offal: 4 days

Milk: 5 days (120 hours)


When using Cobactan MC and Cobactan 25 mg/ml in combination, the withdrawal periods are as follows: Meat and offal: 5 days; Milk: 5 days (120 hours).


PHARMACOLOGICAL PROPERTIES


ATCvet Code:QJ51DA92

Pharmacotherapeutic group:antibacterials for intramammary use, Other β-lactam antibacterials for intramammary use, Cephalosporins and related substances.


Pharmacodynamic properties


Cefquinome is an antibacterial drug of the cephalosporin group which acts by inhibition of cell wall synthesis. It is characterised by its broad therapeutic spectrum of activity and a high stability against penicillinases and beta-lactamases.


Pharmacokinetic particulars


In vitro, Cefquinome has antibiotic activity against common Gram negative and Gram positive bacteria includingSalmonellaspp, Haemophilusspp, Pasteurellaspp,Klebsiella spp, Corynebacterium pyogenes, Escherichia coli, A.pleuropneumoniae, Proteus mirabilis, Staphylococcus aureus, Streptococcus dysgalactiae and Streptococcus uberis.


The product has been developed to treat clinical mastitis caused by sensitive strains of Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, Escherichia coli and other enterobacteria.


The base disperses readily in milk and allows rapid distribution of Cefquinome.


Cefquinome as a fourth generation cephalosporin combines high cellular penetration and ß-lactamase stability.In contrast to cephalosporins of previous generations, cefquinome is not hydrolysed by chromosomally–encoded cephalosporinases of the Amp-C type or by plasmid mediated cephalosporinases of some enterobacterial species. However, some Extended Spectrum beta-lactamases (ESBL) can hydrolyse cefquinome and cephalosporins of other generations. The potential for resistance development against cefquinome is rather low. High-level resistance to cefquinome would require the coincidence of two genetic modifications, i.e. hyperproduction of specific ß-lactamases as well as decreased membrane permeability.


PHARMACEUTICAL PARTICULARS


List of excipients


White soft paraffin

Liquid paraffin


Incompatibilities


None known


Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 30 months


Special precautions for storage


Do not store above 25°C

The syringe must only be used once. Part used syringes should be discarded.


Nature and composition of immediate packaging


White opaque polyethylene syringe containing 75mg cefquinome in packs of 3, 15, 20, 24 and 30 syringes.

Not all presentations may be marketed.


Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.


MARKETING AUTHORISATION HOLDER


Intervet UK Ltd.

Walton Manor

Walton

Milton Keynes

Buckinghamshire

MK7 7AJ


MARKETING AUTHORISATION Number


Vm:01708/4444


DATE OF FIRST AUTHORISATION


Date:29 May 1997


DATE OF REVISION OF TEXT


Date:June 2014


03 June 2014

Page 10 of 10